Cumberland Pharmaceuticals Inc. (CPIX)
$8.65
$-0.32
(-3.57%)
As on 27-Aug-2026 16:00EDT
Market cap
$115 Mln
Revenue (TTM)
$31 Mln
P/E Ratio
--
P/B Ratio
6.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
37.31
-
EV/EBITDA
43.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.7
-
Face value
--
-
Shares outstanding
14,983,107
10 Years Aggregate
CFO
$45.06 Mln
EBITDA
$-2.49 Mln
Net Profit
$-46.10 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cumberland Pharmaceuticals (CPIX)
| 117.3 | 30.9 | 49.9 | 154.4 | 72.3 | 25.7 | 6.9 |
|
BSE Sensex
| -9.1 | 1.1 | 1.2 | -4.8 | 5.8 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cumberland Pharmaceuticals (CPIX)
| 67.9 | 32.1 | -20.4 | -51.8 | 58.3 | -42.7 | -14.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cumberland Pharmaceuticals (CPIX)
|
8.7 | 114.6 | 31.3 | -10.6 | -29.8 | -50 | -- | 6.4 |
| 18.0 | 6,238.0 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 188.9 | |
| 206.3 | 10,883.2 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 130.9 | |
| 78.7 | 15,932.7 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 116.9 | 13,215.0 | 830.8 | 54.9 | 3.2 | 8.1 | 271.7 | 18.7 | |
| 12.2 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 24.6 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 284.5 | 5,707.4 | 290.5 | 197.2 | 82.5 | 19.9 | 29.6 | 5.9 | |
| 69.9 | 6,142.1 | 450.9 | 138.6 | 39.1 | 115.6 | 49 | 31.5 | |
| 153.1 | 9,129.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 20.5 |
Shareholding Pattern
View DetailsAbout Cumberland Pharmaceuticals (CPIX)
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning;... Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H. pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. Read more
-
Founder, Chairman, President & CEO
Mr. A. J. Kazimi MBA
-
Founder, Chairman, President & CEO
Mr. A. J. Kazimi MBA
-
Headquarters
Nashville, TN
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cumberland Pharmaceuticals (CPIX)
What is the current share price of Cumberland Pharmaceuticals Inc (CPIX) Today?
The share price of Cumberland Pharmaceuticals Inc (CPIX) is $8.65 (NASDAQ) as of 27-Aug-2026 16:00 EDT. Cumberland Pharmaceuticals Inc (CPIX) has given a return of 72.34% in the last 3 years.
What is the current PB & PE ratio of Cumberland Pharmaceuticals Inc (CPIX)?
Since, TTM earnings of Cumberland Pharmaceuticals Inc (CPIX) is negative, P/E ratio is not available.
The P/B ratio of Cumberland Pharmaceuticals Inc (CPIX) is 6.41 times as on 21-Aug-2026, a 17 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-20.99 |
2.39 |
2024 |
-5.11 |
1.45 |
2023 |
-4.04 |
0.86 |
2022 |
-5.82 |
0.89 |
2021 |
-19.71 |
1.61 |
What is the 52 Week High and Low of Cumberland Pharmaceuticals Inc (CPIX)?
The 52-week high and low of Cumberland Pharmaceuticals Inc (CPIX) are Rs 9.28 and Rs 1.85 as of 28-Aug-2026.
What is the market cap of Cumberland Pharmaceuticals Inc (CPIX)?
Cumberland Pharmaceuticals Inc (CPIX) has a market capitalisation of $ 115 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cumberland Pharmaceuticals Inc (CPIX)?
Before investing in Cumberland Pharmaceuticals Inc (CPIX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.